We are contrasting ChromaDex Corporation (NASDAQ:CDXC) and Trillium Therapeutics Inc. (NASDAQ:TRIL) on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Trillium Therapeutics Inc.||N/A||0.00||N/A||-2.55||0.00|
Table 1 highlights ChromaDex Corporation and Trillium Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 provides us the return on assets, return on equity and net margins of both businesses.
|Net Margins||Return on Equity||Return on Assets|
|Trillium Therapeutics Inc.||0.00%||0%||0%|
The table given features the ratings and recommendations for ChromaDex Corporation and Trillium Therapeutics Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Trillium Therapeutics Inc.||0||1||1||2.50|
Competitively the average target price of Trillium Therapeutics Inc. is $2.5, which is potential 291.85% upside.
Insider and Institutional Ownership
The shares of both ChromaDex Corporation and Trillium Therapeutics Inc. are owned by institutional investors at 17.7% and 39.41% respectively. 2.3% are ChromaDex Corporation’s share held by insiders. Competitively, insiders own roughly 0.37% of Trillium Therapeutics Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Trillium Therapeutics Inc.||-5.61%||-61.62%||-75.2%||-88.07%||-90.46%||-59.53%|
For the past year ChromaDex Corporation has 1.75% stronger performance while Trillium Therapeutics Inc. has -59.53% weaker performance.
ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.